Reliq Health Technologies Announces Closing of Oversubscribed $10 Million Brokered Private Placement Co-led by Canaccord Genuity and Gravitas Securities
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES
VANCOUVER, British Columbia, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT) or (OTCQB:RQHTF) (“Reliq” or the “Company”), a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community-Based Healthcare, is pleased to announce further to its news release dated December 12, 2017, it successfully closed an oversubscribed private placement (the “Offering”) led by Canaccord Genuity Corp and Gravitas Securities Inc. (together, the “ Agents”) of 8,928,571 Units (the “Units”) of the Company at a price of $1.12 per Unit (the “Unit Price”) for gross proceeds of approximately $10,000,000.
Each Unit consists of one (1) common share of the Company (a “Common Share”) and half of one (1/2) Common Share purchase warrant (each whole Common Share purchase warrant, a “Warrant”). Each of the 4,464,285 Warrants is exercisable to acquire one Common Share (a “Warrant Share”) for a period of two years following the closing date of the Offering at an exercise price of $1.75 per Warrant Share, subject to adjustment in certain events.
The Company intends to use the net proceeds of the Offering for general working capital, product development and customer acquisition.
In connection with the Offering, the Company paid the Agents a cash fee of approximately $800,000 and issued 446,428 Units to the Agents. Additionally, the Company issued 714,285 compensation warrants to the Agents and another selling dealer group member (the “Compensation Warrants”), with each Compensation Warrant entitling the holder to purchase one Unit of the Company at an exercise price of $1.12 for a period of two years following the closing date of the Offering. Each warrant issued under the Units is exercisable into one Common Share of the Company for a period of two years following the closing date of the Offering at an exercise price of $1.75 per Common Share, subject to adjustment in certain events.
All securities issued in connection with the Offering are subject to a four month hold period expiring May 10, 2018.
ON BEHALF OF THE BOARD
“Dr. Lisa Crossley”
CEO and Director